Podcast Episodes
Back to SearchUpdates on the diagnosis, risk stratification and treatment of lower-risk MDS
Episode 216
The treatment and management of lower-risk myelodysplastic syndromes (LR-MDS) has remained a challenge in the field, and several studies are being co…
3 years ago
iwAL 2023 Session III: The relevance of TP53 mutation in AML
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leuk…
3 years ago
iwAL 2023 Session III: The relevance of TP53 mutation in AML
Episode 215
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leu…
3 years ago
iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leu…
3 years ago
iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more
Episode 214
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leu…
3 years ago
iwAL 2023 Session I: Clonal hematopoiesis in AML, early detection and potential therapeutics
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leuk…
3 years ago
iwAL 2023 Session I: Clonal hematopoiesis in AML, early detection and potential therapeutics
Episode 213
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leuk…
3 years ago
Applications of MRD in multiple myeloma: using MRD to guide treatment decisions
Measurable residual disease (MRD) has become a key biomarker in the field of multiple myeloma (MM), and the sensitivity of MRD testing has increased …
3 years ago
Applications of MRD in multiple myeloma: using MRD to guide treatment decisions
Episode 212
Measurable residual disease (MRD) has become a key biomarker in the field of multiple myeloma (MM), and the sensitivity of MRD testing has increased …
3 years ago
Exploring and comparing the curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCL
The treatment and management of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains a major unmet need, and in recent years, the …
3 years, 1 month ago